130 related articles for article (PubMed ID: 36113094)
1. Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients.
Friedli C; Wagner F; Hammer HN; Kamber N; Wiest R; Diem L; Chan A; Salmen A; Hoepner R
Mult Scler; 2023 Jan; 29(1):63-73. PubMed ID: 36113094
[TBL] [Abstract][Full Text] [Related]
2. No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.
Ighani M; Jonas S; Izbudak I; Choi S; Lema-Dopico A; Hua J; O'Connor EE; Harrison DM
Mult Scler; 2020 Feb; 26(2):165-176. PubMed ID: 31573837
[TBL] [Abstract][Full Text] [Related]
3. Leptomeningeal Enhancement on 3D-FLAIR MRI in Multiple Sclerosis: Systematic Observations in Clinical Practice.
Titelbaum DS; Engisch R; Schwartz ED; Napoli SQ; Sloane JA; Samaan S; Katz JD; Lathi ES
J Neuroimaging; 2020 Nov; 30(6):917-929. PubMed ID: 32830899
[TBL] [Abstract][Full Text] [Related]
4. A pilot trial of ocrelizumab for modulation of meningeal enhancement in multiple sclerosis.
Dahal S; Allette YM; Naunton K; Harrison DM
Mult Scler Relat Disord; 2024 Jan; 81():105344. PubMed ID: 38035495
[TBL] [Abstract][Full Text] [Related]
5. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
Zurawski J; Tauhid S; Chu R; Khalid F; Healy BC; Weiner HL; Bakshi R
Mult Scler; 2020 Feb; 26(2):177-187. PubMed ID: 31714181
[TBL] [Abstract][Full Text] [Related]
6. Meningeal contrast enhancement in multiple sclerosis: Assessment of field strength, acquisition delay, and clinical relevance.
Harrison DM; Allette YM; Zeng Y; Cohen A; Dahal S; Choi S; Zhuo J; Hua J
PLoS One; 2024; 19(5):e0300298. PubMed ID: 38809920
[TBL] [Abstract][Full Text] [Related]
7. Highly Sensitive 3-Tesla Real Inversion Recovery MRI Detects Leptomeningeal Contrast Enhancement in Chronic Active Multiple Sclerosis.
Okar SV; Dieckhaus H; Beck ES; Gaitán MI; Norato G; Pham DL; Absinta M; Cortese IC; Fletcher A; Jacobson S; Nair G; Reich DS
Invest Radiol; 2024 Mar; 59(3):243-251. PubMed ID: 37493285
[TBL] [Abstract][Full Text] [Related]
8. Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis.
Ineichen BV; Tsagkas C; Absinta M; Reich DS
Neuroimage Clin; 2022; 33():102939. PubMed ID: 35026625
[TBL] [Abstract][Full Text] [Related]
9. Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study.
Vercellino M; Costantini G; Cogoni M; Lequio L; Sciortino P; De Negri F; Marasciulo S; Valentini C; Bosa C; Garelli P; Rolando A; Calvo A; Morana G; Cavalla P
Mult Scler; 2023 Nov; 29(13):1526-1539. PubMed ID: 37740714
[TBL] [Abstract][Full Text] [Related]
10. Focal cortical atrophy following transient meningeal enhancement in a progressive multiple sclerosis.
Bonnan M; Money P; Desblache P; Marasescu R; Puvilland LM; Demasles S; Dahan C; Krim E; Tucholka A; Doyle S; Barroso B
Neurol Sci; 2021 May; 42(5):1959-1961. PubMed ID: 32995987
[TBL] [Abstract][Full Text] [Related]
11. Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.
Mizell R; Chen H; Lambe J; Saidha S; Harrison DM
Mult Scler; 2022 Mar; 28(3):393-405. PubMed ID: 34125629
[TBL] [Abstract][Full Text] [Related]
12. Leptomeningeal Enhancement at 7T in Multiple Sclerosis: Frequency, Morphology, and Relationship to Cortical Volume.
Harrison DM; Wang KY; Fiol J; Naunton K; Royal W; Hua J; Izbudak I
J Neuroimaging; 2017 Sep; 27(5):461-468. PubMed ID: 28464368
[TBL] [Abstract][Full Text] [Related]
13. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
Absinta M; Cortese IC; Vuolo L; Nair G; de Alwis MP; Ohayon J; Meani A; Martinelli V; Scotti R; Falini A; Smith BR; Nath A; Jacobson S; Filippi M; Reich DS
Neurology; 2017 Apr; 88(15):1439-1444. PubMed ID: 28283598
[TBL] [Abstract][Full Text] [Related]
14. Use of Magnetic Resonance Imaging to Visualize Leptomeningeal Inflammation in Patients With Multiple Sclerosis: A Review.
Zurawski J; Lassmann H; Bakshi R
JAMA Neurol; 2017 Jan; 74(1):100-109. PubMed ID: 27893883
[TBL] [Abstract][Full Text] [Related]
15. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.
Bhargava P; Wicken C; Smith MD; Strowd RE; Cortese I; Reich DS; Calabresi PA; Mowry EM
Mult Scler Relat Disord; 2019 May; 30():136-140. PubMed ID: 30771580
[TBL] [Abstract][Full Text] [Related]
16. Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study.
Bergsland N; Ramasamy D; Tavazzi E; Hojnacki D; Weinstock-Guttman B; Zivadinov R
AJNR Am J Neuroradiol; 2019 Apr; 40(4):620-625. PubMed ID: 30872420
[TBL] [Abstract][Full Text] [Related]
17. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
[TBL] [Abstract][Full Text] [Related]
18. Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation.
Marchi L; Mariottini A; Viti V; Bianchi A; Nozzoli C; Repice AM; Boncompagni R; Ginestroni A; Damato V; Barilaro A; Chiti S; Saccardi R; Fainardi E; Massacesi L
Front Neurol; 2024; 15():1373385. PubMed ID: 38899059
[TBL] [Abstract][Full Text] [Related]
19. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.
Zivadinov R; Medin J; Khan N; Korn JR; Chitnis T; Naismith RT; Alvarez E; Dwyer MG; Bergsland N; Carl E; Silva D; Weinstock-Guttman B;
Mult Scler Relat Disord; 2019 Jan; 27():65-73. PubMed ID: 30342416
[TBL] [Abstract][Full Text] [Related]
20. No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study.
Zivadinov R; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Kolodny S; Silva D; Medin J; Weinstock-Guttman B;
Curr Med Res Opin; 2018 Aug; 34(8):1431-1440. PubMed ID: 29648900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
